Novo Nordisk Pharmatech A/S products

Recombinant Insulin is an essential component in modern biomanufacturing processes, developed by Novo Nordisk Pharmatech. It plays a crucial role in enhancing cell proliferation and boosting the production of therapeutic proteins, viral vectors for advanced therapies, and viruses for vaccines. Its unique biological properties make it vital in various cell culture applications, supporting the growth of cells used in monoclonal antibodies, cell and gene therapies, and vaccines. Approved by regulatory bodies globally, this insulin variant is known for its high-quality and consistent performance, proving beneficial in improving the quality and efficiency of cell culture systems. Additionally, its use extends to pluripotent stem cells and cell-based vaccines, contributing to therapies for conditions such as arthritis, cancer, and multiple sclerosis. The product helps accelerate time-to-market for crucial pharmaceuticals, reaching patients worldwide.

Recombinant Insulin, commercially known as Insulin Human AF, is an engineered protein made from human insulin crystals, crafted through advanced microbial expression systems in yeast. This product plays a vital role in binding to insulin receptors, which is crucial for triggering key intracellular signaling pathways that govern cellular growth, differentiation, and glucose uptake. It is instrumental in improving cell culture proliferation and enhancing protein yields by facilitating transcription, DNA synthesis, replication, and protein translocation. This insulin variant is critical for the manufacture of monoclonal antibodies, virus vaccines, gene therapy medications, and other biotech innovations approved globally by regulatory authorities. Available in variable packaging sizes, it supports process optimization and high-yield cellular products.

TrypsiNNex is a recombinant trypsin enzyme designed for animal-free biopharmaceutical manufacturing. It features a sequence identical to porcine trypsin, offering a direct replacement option that maintains high levels of β-trypsin. This product is expressed in Escherichia coli as an inactive precursor which is activated during the final phases to ensure a high content of β-trypsin, a crucial quality indicator for consistency in proteolytic patterns. The enzyme’s autolytic properties are controlled throughout production, reducing undesirable activity from intermediate forms like Ψ-trypsin. TrypsiNNex is produced following the Joint Good Manufacturing Practices for Pharmaceutical Excipients and applicable ICH guidelines. With enzymatic activity exceeding 333,000 USP units/ml and a purity level of at least 90%, it supports high-quality processing of precursor proteins. It is supplied in a formulation of 10 mM HCl and 20 mM CaCl2, adhering to strict bioburden controls to guarantee stability and integrity.